Roche’s Lunsumio and Polivy combination significantly prolongs remission for people with relapsed or refractory large B-cell lymphoma

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx

Sanner commences manufacturing critical injection-molded components in USA

The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space

UFlex introduces FSSAI compliant single-pellet solution for food packaging

UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials

Lupin and Sino Universal Pharmaceuticals sign license and supply agreement for tiotropium DPI in China

SUP will obtain regulatory approvals for selling Tiotropium DPI in China

AstraZeneca collaborates with CSPC Pharmaceuticals focused on AI-enabled research

The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities

Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease

Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biological driver of Parkinson’s disease progression

NVIDIA partners with Novo Nordisk and DCAI to advance drug discovery

The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

Mezzion secures $20 million funding to advance Phase 3 clinical development of Udenafil for fontan patients